New anticancer drug candidates sulfonamides as selective hCA IX or hCA XII inhibitors
| Autor: | Cem Yamali, Kaspars Tars, Claudiu T. Supuran, Halise Inci Gul, Dilan Ozmen Ozgun, Janis Leitans, Andris Kazaks, Andrea Angeli, Hiroshi Sakagami |
|---|---|
| Přispěvatelé: | Belirlenecek, angeli, andrea -- 0000-0002-1470-7192, Sakagami, Hiroshi -- 0000-0001-8001-2121, Tars, Kaspars -- 0000-0001-8421-9023, Andris -- 0000-0003-4964-0984, Yamali, Cem -- 0000-0002-4833-7900, Gul, Halise Inci -- 0000-0001-6164-9602 |
| Rok vydání: | 2018 |
| Předmět: |
Stereochemistry
Antineoplastic Agents Pyrazoline Sulfonamide Carbonic anhydrases 01 natural sciences Biochemistry Isozyme Cell Line Structure-Activity Relationship chemistry.chemical_compound Antigens Neoplasm Drug Discovery medicine Humans Carbonic Anhydrase IX Carbonic Anhydrase Inhibitors Molecular Biology Cell Proliferation Sulfonamides Dose-Response Relationship Drug Molecular Structure 010405 organic chemistry Aryl Organic Chemistry Sulfonamide (medicine) Anticancer drug 0104 chemical sciences Isoenzymes 010404 medicinal & biomolecular chemistry Anticancer Dental cells chemistry Pyrazoles Drug Screening Assays Antitumor Selectivity medicine.drug |
| Zdroj: | Bioorganic Chemistry. 77:411-419 |
| ISSN: | 0045-2068 |
| Popis: | In this study, new 4-13-(aryl)-5-substitutedphenyl-4,5-dihydro-1H-pyrazole-1-yllbenzensulfonamides (19-36) were synthesized and evaluated their cytotoxic/anticancer and CA inhibitory effects. According to results obtained, the compounds 34 (4-[5-(2,3,4-trimethoxyphenyl)-3-(thiophen-2-yl)4,5-dihydro-1H-pyrazole-1-yl benzensulfonamide, Potency-Selectivity Expression (PSE) = 141) and 36 (44 543,4,5-trimethoxyphenyl)-3-( thiophen-2-yl)-4,5-dihydro-1H-pyrazole-1-yl benzensulfonamide, PSE = 54.5) were found the leader anticancer compounds with the highest PSE values. In CA inhibitory studies, the compounds 36 and 24 (4-[5-(3,4,5-trimethoxyphenyl) 3 (4 fluorophenyl)-4,5-dihydro-1H-pyrazole-1-yl]benzensulfonamide) were found the leader CA inhibitors depending on selectivity ratios. The compound 36 was a selective inhibitor of hCA XII isoenzyme (hCA l/hCA XII = 1250 and hCA II/hCA XII = 224) while the compound 24 was a selective inhibitor of hCA IX isoenzyme (hCA l/hCA IX = 161 and hCA II/hCA IX = 177). The compounds 24, 34, and 36 can be considered to develop new anticancer drug candidates. (C) 2018 Elsevier Inc. All rights reserved. TUBITAK [2016-115S694] This work was supported by the TUBITAK (Project Number: 2016-115S694). Authors thank to Dr. Yusuf Ozkay and MSc. Serkan Levent (Anadolu University, Faculty of Pharmacy, Eskisehir, Turkey) for HRMS analysis and Ataturk University, Faculty of Science, Department of Chemistry for NMRs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect